$12.35
+4.22%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
Market Cap
$776.18M
MomentumView details →
1D Return
+4.22%
YTD Return
−35.92%
RSI (14)
36.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
Market Cap
$776.18M
RSI (14)
36.0
MomentumView details →
1D Return
+4.22%
YTD Return
−35.92%
SummaryUpdated Jun 1, 2026
DBV Technologies S.A. (NASDAQ:DBVT) is a French clinical-stage biopharmaceutical company founded in 2002 and headquartered in Montrouge, France. The company went public on NASDAQ in October 2014 and specializes in developing epicutaneous immunotherapy treatments, which deliver therapeutic compounds through the skin rather than through injections or oral medications. DBV Technologies is primarily focused on developing treatments for food allergies, with its lead product candidate being Viaskin Peanut for treating peanut allergies in children and toddlers.
Similar companies
Latest newsMore news →
DBV Technologies sold approximately $50 million of American Depositary Shares through its At-The-Market program on Nasdaq to RA Capital Management, with Citizens JMP Securities acting as sales agent.47d agoDBV Technologies filed a prospectus supplement to refresh its at-the-market offering program for up to $150 million of American Depositary Shares.60d ago